# EDGAR Filing Document

**Accession Number:** 0001485894
**File Stem:** 0002071691-26-007429
**Filing Date:** 2026-3
**Character Count:** 43134
**Document Hash:** 226ad8910ff078c0d5758cfcf054a205
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002071691-26-007429.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0002071691-26-007429

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260131

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**PERIOD START**: 20261031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** J.P. Morgan Exchange-Traded Fund Trust
- **CENTRAL INDEX KEY:** 0001485894

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-22903
- **FILM NUMBER:** 26805571

**BUSINESS ADDRESS:**
- **STREET 1:** 390 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (800) 480-4111

**MAIL ADDRESS:**
- **STREET 1:** 390 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

## Series and Classes Contracts Data

### JPMorgan Healthcare Leaders ETF (Series ID: S000080528)

| Class ID   | Class Name                      | Ticker Symbol   |
|:---|:---|:---|
| C000243005 | JPMorgan Healthcare Leaders ETF | JDOC            |

## Nport-Ex

**JPMorgan Healthcare Leaders ETF**

**Schedule of Portfolio Investments as of January 31, 2026**

**(Unaudited)** 

---

| |
|:---|
| &nbsp;&nbsp; THE "UNAUDITED EXCHANGE-TRADED FUNDS HOLDINGS" <br> LIST ("the List") IS TO BE USED FOR REPORTING PURPOSES <br> ONLY. IT IS NOT TO BE REPRODUCED FOR USE AS <br> ADVERTISING OR SALES LITERATURE WITH THE GENERAL <br> PUBLIC. The list is submitted for the general information of the <br> shareholders of the Fund. It is not authorized for distribution to <br> prospective investors in the Fund unless preceded or accompanied by a <br> prospectus. The list has been created from the books and records of <br> the Fund. Holdings are available 60 days after the fund's fiscal quarter, <br> using a trade date accounting convention, by contacting the appropriate <br> service center. The list is subject to change without notice. The list is <br> for informational purposes only and is not intended as an offer or <br> solicitation with respect to the purchase or sale of any security.<br>|
| &nbsp;&nbsp; JPMorgan Asset Management is the marketing name for the asset <br> management business of J.P. Morgan Chase & Co.<br>|
| J.P. Morgan Distribution Services, Inc., member FINRA. |
|© J.P. Morgan Chase & Co., 2026. |

---

------

**JPMorgan Healthcare Leaders ETF**

**SCHEDULE OF PORTFOLIO INVESTMENTS**

AS OF January 31, 2026 (Unaudited)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| **INVESTMENTS** | **SHARES** | **VALUE($)** |
| **Common Stocks — 99.3%** | **Common Stocks — 99.3%** | **Common Stocks — 99.3%** |
| **Belgium — 1.9%** | **Belgium — 1.9%** | **Belgium — 1.9%** |
| &nbsp;&nbsp;&nbsp; UCB SA | &nbsp;&nbsp;&nbsp;&nbsp; 544 | &nbsp;&nbsp;&nbsp;&nbsp; 165771 |
| **Canada — 0.4%** | **Canada — 0.4%** | **Canada — 0.4%** |
| &nbsp;&nbsp;&nbsp; Xenon Pharmaceuticals, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 913 | &nbsp;&nbsp;&nbsp;&nbsp; 37442 |
| **Denmark — 5.3%** | **Denmark — 5.3%** | **Denmark — 5.3%** |
| &nbsp;&nbsp;&nbsp; Ascendis Pharma A/S, ADR \* | &nbsp;&nbsp;&nbsp;&nbsp; 297 | &nbsp;&nbsp;&nbsp;&nbsp; 67152 |
| &nbsp;&nbsp;&nbsp; Genmab A/S, ADR \* | &nbsp;&nbsp;&nbsp;&nbsp; 393 | &nbsp;&nbsp;&nbsp;&nbsp; 12824 |
| &nbsp;&nbsp;&nbsp; Genmab A/S \* | &nbsp;&nbsp;&nbsp;&nbsp; 199 | &nbsp;&nbsp;&nbsp;&nbsp; 64831 |
| &nbsp;&nbsp;&nbsp; Novo Nordisk A/S, Class B | &nbsp;&nbsp;&nbsp;&nbsp; 5388 | &nbsp;&nbsp;&nbsp;&nbsp; 319935 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp; 464742 |
| **France — 2.1%** | **France — 2.1%** | **France — 2.1%** |
| &nbsp;&nbsp;&nbsp; EssilorLuxottica SA | &nbsp;&nbsp;&nbsp;&nbsp; 609 | &nbsp;&nbsp;&nbsp;&nbsp; 186169 |
| **Germany — 2.2%** | **Germany — 2.2%** | **Germany — 2.2%** |
| &nbsp;&nbsp;&nbsp; Fresenius SE & Co. KGaA | &nbsp;&nbsp;&nbsp;&nbsp; 1875 | &nbsp;&nbsp;&nbsp;&nbsp; 104883 |
| &nbsp;&nbsp;&nbsp; Sartorius AG (Preference) | &nbsp;&nbsp;&nbsp;&nbsp; 298 | &nbsp;&nbsp;&nbsp;&nbsp; 83289 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp; 188172 |
| **Israel — 1.2%** | **Israel — 1.2%** | **Israel — 1.2%** |
| &nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd. \* | &nbsp;&nbsp;&nbsp;&nbsp; 3182 | &nbsp;&nbsp;&nbsp;&nbsp; 107960 |
| **Japan — 2.6%** | **Japan — 2.6%** | **Japan — 2.6%** |
| &nbsp;&nbsp;&nbsp; Daiichi Sankyo Co. Ltd. | &nbsp;&nbsp;&nbsp;&nbsp; 3200 | &nbsp;&nbsp;&nbsp;&nbsp; 58623 |
| &nbsp;&nbsp;&nbsp; Hoya Corp. | &nbsp;&nbsp;&nbsp;&nbsp; 1000 | &nbsp;&nbsp;&nbsp;&nbsp; 167756 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp; 226379 |
| **Netherlands — 2.4%** | **Netherlands — 2.4%** | **Netherlands — 2.4%** |
| &nbsp;&nbsp;&nbsp; Argenx SE \* | &nbsp;&nbsp;&nbsp;&nbsp; 245 | &nbsp;&nbsp;&nbsp;&nbsp; 206038 |
| **Switzerland — 1.8%** | **Switzerland — 1.8%** | **Switzerland — 1.8%** |
| &nbsp;&nbsp;&nbsp; Lonza Group AG (Registered) | &nbsp;&nbsp;&nbsp;&nbsp; 238 | &nbsp;&nbsp;&nbsp;&nbsp; 161709 |
| **United Kingdom — 5.3%** | **United Kingdom — 5.3%** | **United Kingdom — 5.3%** |
| &nbsp;&nbsp;&nbsp; AstraZeneca plc | &nbsp;&nbsp;&nbsp;&nbsp; 2242 | &nbsp;&nbsp;&nbsp;&nbsp; 417716 |
| &nbsp;&nbsp;&nbsp; Convatec Group plc (a) | &nbsp;&nbsp;&nbsp;&nbsp; 16261 | &nbsp;&nbsp;&nbsp;&nbsp; 51293 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp; 469009 |
| **United States — 74.1%** | **United States — 74.1%** | **United States — 74.1%** |
| &nbsp;&nbsp;&nbsp; AbbVie, Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 2157 | &nbsp;&nbsp;&nbsp;&nbsp; 481033 |
| &nbsp;&nbsp;&nbsp; Align Technology, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 228 | &nbsp;&nbsp;&nbsp;&nbsp; 37171 |
| &nbsp;&nbsp;&nbsp; Alnylam Pharmaceuticals, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 84 | &nbsp;&nbsp;&nbsp;&nbsp; 28397 |
| &nbsp;&nbsp;&nbsp; Apogee Therapeutics, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 992 | &nbsp;&nbsp;&nbsp;&nbsp; 64986 |
| &nbsp;&nbsp;&nbsp; Axsome Therapeutics, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 429 | &nbsp;&nbsp;&nbsp;&nbsp; 79043 |
| &nbsp;&nbsp;&nbsp; Biogen, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 460 | &nbsp;&nbsp;&nbsp;&nbsp; 82749 |
| &nbsp;&nbsp;&nbsp; Bio-Techne Corp. | &nbsp;&nbsp;&nbsp;&nbsp; 633 | &nbsp;&nbsp;&nbsp;&nbsp; 40569 |
| &nbsp;&nbsp;&nbsp; Boston Scientific Corp. \* | &nbsp;&nbsp;&nbsp;&nbsp; 2506 | &nbsp;&nbsp;&nbsp;&nbsp; 234386 |
| &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Co. | &nbsp;&nbsp;&nbsp;&nbsp; 3881 | &nbsp;&nbsp;&nbsp;&nbsp; 213649 |
| &nbsp;&nbsp;&nbsp; Cardinal Health, Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 679 | &nbsp;&nbsp;&nbsp;&nbsp; 145904 |
| &nbsp;&nbsp;&nbsp; CG oncology, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 1052 | &nbsp;&nbsp;&nbsp;&nbsp; 54757 |
| &nbsp;&nbsp;&nbsp; Cigna Group (The) | &nbsp;&nbsp;&nbsp;&nbsp; 142 | &nbsp;&nbsp;&nbsp;&nbsp; 38924 |
| &nbsp;&nbsp;&nbsp; CVS Health Corp. | &nbsp;&nbsp;&nbsp;&nbsp; 2827 | &nbsp;&nbsp;&nbsp;&nbsp; 210668 |
| &nbsp;&nbsp;&nbsp; Cytokinetics, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 679 | &nbsp;&nbsp;&nbsp;&nbsp; 42906 |

---

------

**JPMorgan Healthcare Leaders ETF**

**SCHEDULE OF PORTFOLIO INVESTMENTS**

AS OF January 31, 2026 (Unaudited) (continued)

---

| | | |
|:---|:---|:---|
| **INVESTMENTS** | **SHARES** | **VALUE($)** |
| **Common Stocks — continued** | **Common Stocks — continued** | **Common Stocks — continued** |
| **United States — continued** | **United States — continued** | **United States — continued** |
| &nbsp;&nbsp;&nbsp; Danaher Corp. | &nbsp;&nbsp;&nbsp;&nbsp; 1216 | &nbsp;&nbsp;&nbsp;&nbsp; 266170 |
| &nbsp;&nbsp;&nbsp; Disc Medicine, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 759 | &nbsp;&nbsp;&nbsp;&nbsp; 58686 |
| &nbsp;&nbsp;&nbsp; Dyne Therapeutics, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 3200 | &nbsp;&nbsp;&nbsp;&nbsp; 57248 |
| &nbsp;&nbsp;&nbsp; Edwards Lifesciences Corp. \* | &nbsp;&nbsp;&nbsp;&nbsp; 1781 | &nbsp;&nbsp;&nbsp;&nbsp; 144902 |
| &nbsp;&nbsp;&nbsp; Eli Lilly & Co. | &nbsp;&nbsp;&nbsp;&nbsp; 609 | &nbsp;&nbsp;&nbsp;&nbsp; 631624 |
| &nbsp;&nbsp;&nbsp; HCA Healthcare, Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 60 | &nbsp;&nbsp;&nbsp;&nbsp; 29296 |
| &nbsp;&nbsp;&nbsp; Immunome, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 2513 | &nbsp;&nbsp;&nbsp;&nbsp; 61870 |
| &nbsp;&nbsp;&nbsp; Intuitive Surgical, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 235 | &nbsp;&nbsp;&nbsp;&nbsp; 118492 |
| &nbsp;&nbsp;&nbsp; Ionis Pharmaceuticals, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 943 | &nbsp;&nbsp;&nbsp;&nbsp; 77958 |
| &nbsp;&nbsp;&nbsp; IQVIA Holdings, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 544 | &nbsp;&nbsp;&nbsp;&nbsp; 125202 |
| &nbsp;&nbsp;&nbsp; Johnson & Johnson | &nbsp;&nbsp;&nbsp;&nbsp; 3061 | &nbsp;&nbsp;&nbsp;&nbsp; 695612 |
| &nbsp;&nbsp;&nbsp; McKesson Corp. | &nbsp;&nbsp;&nbsp;&nbsp; 221 | &nbsp;&nbsp;&nbsp;&nbsp; 183697 |
| &nbsp;&nbsp;&nbsp; Medtronic plc | &nbsp;&nbsp;&nbsp;&nbsp; 2643 | &nbsp;&nbsp;&nbsp;&nbsp; 272123 |
| &nbsp;&nbsp;&nbsp; Merck & Co., Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 3953 | &nbsp;&nbsp;&nbsp;&nbsp; 435897 |
| &nbsp;&nbsp;&nbsp; Neurocrine Biosciences, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 498 | &nbsp;&nbsp;&nbsp;&nbsp; 67758 |
| &nbsp;&nbsp;&nbsp; Novartis AG (Registered) | &nbsp;&nbsp;&nbsp;&nbsp; 672 | &nbsp;&nbsp;&nbsp;&nbsp; 99705 |
| &nbsp;&nbsp;&nbsp; Nuvalent, Inc., Class A \* | &nbsp;&nbsp;&nbsp;&nbsp; 224 | &nbsp;&nbsp;&nbsp;&nbsp; 23047 |
| &nbsp;&nbsp;&nbsp; Regeneron Pharmaceuticals, Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 247 | &nbsp;&nbsp;&nbsp;&nbsp; 183138 |
| &nbsp;&nbsp;&nbsp; Revolution Medicines, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 93 | &nbsp;&nbsp;&nbsp;&nbsp; 9016 |
| &nbsp;&nbsp;&nbsp; Roche Holding AG | &nbsp;&nbsp;&nbsp;&nbsp; 564 | &nbsp;&nbsp;&nbsp;&nbsp; 256473 |
| &nbsp;&nbsp;&nbsp; Sionna Therapeutics, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 106 | &nbsp;&nbsp;&nbsp;&nbsp; 4480 |
| &nbsp;&nbsp;&nbsp; Stryker Corp. | &nbsp;&nbsp;&nbsp;&nbsp; 406 | &nbsp;&nbsp;&nbsp;&nbsp; 150041 |
| &nbsp;&nbsp;&nbsp; Terns Pharmaceuticals, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 903 | &nbsp;&nbsp;&nbsp;&nbsp; 31244 |
| &nbsp;&nbsp;&nbsp; Thermo Fisher Scientific, Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 225 | &nbsp;&nbsp;&nbsp;&nbsp; 130187 |
| &nbsp;&nbsp;&nbsp; United Therapeutics Corp. \* | &nbsp;&nbsp;&nbsp;&nbsp; 136 | &nbsp;&nbsp;&nbsp;&nbsp; 63851 |
| &nbsp;&nbsp;&nbsp; UnitedHealth Group, Inc. | &nbsp;&nbsp;&nbsp;&nbsp; 1067 | &nbsp;&nbsp;&nbsp;&nbsp; 306154 |
| &nbsp;&nbsp;&nbsp; Vertex Pharmaceuticals, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 344 | &nbsp;&nbsp;&nbsp;&nbsp; 161646 |
| &nbsp;&nbsp;&nbsp; Viridian Therapeutics, Inc. \* | &nbsp;&nbsp;&nbsp;&nbsp; 1743 | &nbsp;&nbsp;&nbsp;&nbsp; 57519 |
| &nbsp;&nbsp;&nbsp; Waters Corp. \* | &nbsp;&nbsp;&nbsp;&nbsp; 116 | &nbsp;&nbsp;&nbsp;&nbsp; 43004 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp; 6501182 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Common Stocks <br>(Cost $7,165,508)<br>|  | &nbsp;&nbsp;&nbsp;&nbsp; 8714573 |
| **Total Investments — 99.3%** <br>**(Cost $7,165,508)**<br>|  | &nbsp;&nbsp;&nbsp;&nbsp; **8714573** |
| **Other Assets in Excess of Liabilities — 0.7%** |  | &nbsp;&nbsp;&nbsp;&nbsp; **63028** |
| **NET ASSETS — 100.0%** |  | &nbsp;&nbsp;&nbsp;&nbsp; **8777601** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<br>Percentages indicated are based on net assets.<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Abbreviations** |  |
| ADR | American Depositary Receipt |
| Preference | A special type of equity investment that shares in the earnings of the company, has limited voting rights, and may have a dividend preference. Preference <br> shares may also have liquidation preference.<br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

\* Non-income producing security. 

(a) Security exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. Regulation S applies to securities offerings that are made outside of the United States and do not involve direct selling efforts in the United States and as such may have restrictions on resale. 

------

**JPMorgan Healthcare Leaders ETF**

**SCHEDULE OF PORTFOLIO INVESTMENTS**

AS OF January 31, 2026 (Unaudited) (continued)

**Summary of Investments by Industry, January 31, 2026**

The following table represents the portfolio investments of the Fund by industry classifications as a percentage of total investments:

---

| | |
|:---|:---|
| **INDUSTRY** | **PERCENT OF** <br>**TOTAL** <br>**INVESTMENTS**<br>|
| Pharmaceuticals | 40.3<br> %<br>|
| Biotechnology | 22.6 |
| Health Care Equipment & Supplies | 15.6 |
| Health Care Providers & Services | 11.7 |
| Life Sciences Tools & Services | 9.8 |

---

------

**JPMorgan Healthcare Leaders ETF**

**SCHEDULE OF PORTFOLIO INVESTMENTS**

AS OF January 31, 2026 (Unaudited) (continued)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**A. Valuation of Investments**— Investments are valued in accordance with U.S. generally accepted accounting principles ("GAAP") and the Fund's valuation policies set forth by, and under the supervision and responsibility of, the Board of Trustees of the Trust (the "Board"), which established the following approach to valuation, as described more fully below: (i) investments for which market quotations are readily available shall be valued at their market value and (ii) all other investments for which market quotations are not readily available shall be valued at their fair value as determined in good faith by the Board.

Under Section 2(a)(41) of the Investment Company Act of 1940 (the "1940 Act"), the Board is required to determine fair value for securities that do not have readily available market quotations. Pursuant to Rule 2a-5 under the 1940 Act (Good Faith Determinations of Fair Value), the Board may designate the performance of these fair valuation determinations to a valuation designee. The Board has designated the Adviser as the "Valuation Designee" to perform fair valuation determinations for the Fund on behalf of the Board subject to appropriate oversight by the Board. The Adviser, as Valuation Designee, leverages the J.P. Morgan Asset Management Americas Valuation Committee ("AVC") to help oversee and carry out the policies for the valuation of investments held in the Fund. The Adviser, as Valuation Designee, remains responsible for the valuation determinations.

This oversight by the AVC includes monitoring the appropriateness of fair values based on results of ongoing valuation oversight including, but not limited to, consideration of macro or security specific events, market events, and pricing vendor and broker due diligence. The Administrator is responsible for discussing and assessing the potential impacts to the fair values on an ongoing basis, and, at least on a quarterly basis, with the AVC and the Board.

Equities and other exchange-traded instruments are valued at the last sale price or official market closing price on the primary exchange on which the instrument is traded before the net asset value ("NAV") of the Fund is calculated on a valuation date. Certain foreign equity instruments are valued by applying international fair value factors provided by an approved Pricing Service. The factors seek to adjust the local closing price for movements of local markets post-closing, but prior to the time the NAV is calculated.

Investments in open-end investment companies ("Underlying Funds") are valued at each Underlying Fund's NAV per share as of the report date.

Valuations reflected in this report are as of the report date. As a result, changes in valuation due to market events and/or issuer-related events after the report date and prior to issuance of the report are not reflected herein.

The various inputs that are used in determining the valuation of the Fund's investments are summarized into the three broad levels listed below.

• Level 1 — Unadjusted inputs using quoted prices in active markets for identical investments.

• Level 2 — Other significant observable inputs including, but not limited to, quoted prices for similar investments, inputs other than quoted prices that are observable for investments (such as interest rates, prepayment speeds, credit risk, etc.) or other market corroborated inputs.

• Level 3 — Significant inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Fund's assumptions in determining the fair value of investments).

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input, both individually and in the aggregate, that is significant to the fair value measurement. The inputs or methodology used for valuing instruments are not necessarily an indication of the risk associated with investing in those instruments.

The following table represents each valuation input as presented on the Schedule of Portfolio Investments:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp; **Level 1** <br>Quoted prices<br>| &nbsp;&nbsp;&nbsp;&nbsp; **Level 2** <br>Other significant <br>observable inputs<br>| &nbsp;&nbsp;&nbsp;&nbsp; **Level 3** <br>Significant <br>unobservable inputs<br>| **Total** |
| **Investments in Securities** |  |  |  |  |
| Common Stocks |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Belgium | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $165771 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $165771 |
| &nbsp;&nbsp;&nbsp; Canada | &nbsp;&nbsp;&nbsp;&nbsp; 37442 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 37442 |
| &nbsp;&nbsp;&nbsp; Denmark | &nbsp;&nbsp;&nbsp;&nbsp; 79976 | &nbsp;&nbsp;&nbsp;&nbsp; 384766 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 464742 |
| &nbsp;&nbsp;&nbsp; France | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 186169 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 186169 |
| &nbsp;&nbsp;&nbsp; Germany | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 188172 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 188172 |
| &nbsp;&nbsp;&nbsp; Israel | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 107960 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 107960 |
| &nbsp;&nbsp;&nbsp; Japan | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 226379 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 226379 |
| &nbsp;&nbsp;&nbsp; Netherlands | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 206038 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 206038 |

---

------

**JPMorgan Healthcare Leaders ETF**

**SCHEDULE OF PORTFOLIO INVESTMENTS**

AS OF January 31, 2026 (Unaudited) (continued)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp; **Level 1**<br> Quoted prices<br>| &nbsp;&nbsp;&nbsp;&nbsp; **Level 2**<br> Other significant<br> observable inputs<br>| &nbsp;&nbsp;&nbsp;&nbsp; **Level 3**<br> Significant<br> unobservable inputs<br>| **Total** |
| &nbsp;&nbsp;&nbsp; Switzerland | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $161709 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $161709 |
| &nbsp;&nbsp;&nbsp; United Kingdom | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 469009 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 469009 |
| &nbsp;&nbsp;&nbsp; United States | &nbsp;&nbsp;&nbsp;&nbsp; 6145004 | &nbsp;&nbsp;&nbsp;&nbsp; 356178 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 6501182 |
| &nbsp;&nbsp;&nbsp; Total Common Stocks | &nbsp;&nbsp;&nbsp;&nbsp; 6262422 | &nbsp;&nbsp;&nbsp;&nbsp; 2452151 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 8714573 |
| **Total Investments in Securities** | &nbsp;&nbsp;&nbsp;&nbsp; $6262422 | &nbsp;&nbsp;&nbsp;&nbsp; $2452151 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $8714573 |

---

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** J.P. Morgan Exchange-Traded Fund Trust

- **b. Investment Company Act file number:** 811-22903

- **c. CIK number of Registrant:** 0001485894

- **d. LEI of Registrant:** 5493001E1K1DVWDV2464

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 390 Madison Avenue

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 844-457-6383

**Item A.2. Information about the Series.**

- **a. Name of Series:** JPMorgan Healthcare Leaders ETF

- **b. EDGAR series identifier (if any):** S000080528

- **c. LEI of Series:** 5493000GRVENCXRUA282

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-10-31

- **b. Date as of which information is reported:** 2026-01-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $8781031.04

**Total Liabilities:** $4111.27

**Net Assets:** $8776919.77

**Cash Not Reported:** $66277.28

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000243005 | 8.21%                | -1.56%               | 1.14%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $127942.67               | $547890.16                                 |
| Month 2  | $52842.86                | $-196443.86                                |
| Month 3  | $15362.84                | $80919.70                                  |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                                | Title                               | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Apogee Therapeutics, Inc.           | Apogee Therapeutics, Inc.           | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1116 | NS      | $73109.16     | 0.83%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals, Inc.         | Ionis Pharmaceuticals, Inc.         | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |       943 | NS      | $77957.81     | 0.89%             |  |  |  | No            |                  1 | On Loan: No      |
| United Therapeutics Corp.           | United Therapeutics Corp.           | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |       136 | NS      | $63850.64     | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Japanese Yen                        | Japanese Yen                        | CUSIP: N/A<br>LEI: N/A                        | Short            | STIV             |  | JP        |        -1 | OU      | $-0.01        | -0.00%            |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co.            | Bristol-Myers Squibb Co.            | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |      3881 | NS      | $213649.05    | 2.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Waters Corp.                        | Waters Corp.                        | CUSIP: 941848103<br>LEI: 5T547R1474YC9HOD8Q74 | Long             | EC               | CORP              | US        |       116 | NS      | $43003.52     | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co.                     | Eli Lilly & Co.                     | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |       609 | NS      | $631624.35    | 7.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp.                       | Danaher Corp.                       | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |      1268 | NS      | $277552.52    | 3.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp.                       | Stryker Corp.                       | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |       406 | NS      | $150041.36    | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences, Inc.        | Neurocrine Biosciences, Inc.        | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |       498 | NS      | $67757.88     | 0.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp.             | Boston Scientific Corp.             | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |      2272 | NS      | $212500.16    | 2.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics, Inc.             | Dyne Therapeutics, Inc.             | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      3200 | NS      | $57248.00     | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen, Inc.                        | Biogen, Inc.                        | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |       460 | NS      | $82749.40     | 0.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Sartorius AG                        | Sartorius AG (Preference)           | CUSIP: N/A<br>LEI: 529900EQV2DY4FOAMU38       | Long             | EC               | CORP              | DE        |       327 | NS      | $91394.21     | 1.04%             |  |  |  | No            |                  2 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries Ltd. | CUSIP: N/A<br>LEI: 549300BAFGM4RC74ZJ94       | Long             | EC               | CORP              | IL        |      3182 | NS      | $107960.10    | 1.23%             |  |  |  | No            |                  2 | On Loan: No      |
| Genmab A/S                          | Genmab A/S                          | CUSIP: 372303206<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |       393 | NS      | $12823.59     | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Viridian Therapeutics, Inc.         | Viridian Therapeutics, Inc.         | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |      1743 | NS      | $57519.00     | 0.66%             |  |  |  | No            |                  1 | On Loan: No      |
| EssilorLuxottica SA                 | EssilorLuxottica SA                 | CUSIP: N/A<br>LEI: 549300M3VH1A3ER1TB49       | Long             | EC               | CORP              | FR        |       551 | NS      | $168438.54    | 1.92%             |  |  |  | No            |                  2 | On Loan: No      |
| Argenx SE                           | Argenx SE                           | CUSIP: N/A<br>LEI: 7245009C5FZE6G9ODQ71       | Long             | EC               | CORP              | NL        |        27 | NS      | $22706.23     | 0.26%             |  |  |  | No            |                  2 | On Loan: No      |
| Revolution Medicines, Inc.          | Revolution Medicines, Inc.          | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |       455 | NS      | $44112.25     | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                   | Johnson & Johnson                   | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |      2868 | NS      | $651753.00    | 7.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co., Inc.                   | Merck & Co., Inc.                   | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |      4066 | NS      | $448357.82    | 5.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Disc Medicine, Inc.                 | Disc Medicine, Inc.                 | CUSIP: 254604101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       759 | NS      | $58685.88     | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp.                    | Bio-Techne Corp.                    | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |       633 | NS      | $40568.97     | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunome, Inc.                      | Immunome, Inc.                      | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2513 | NS      | $61870.06     | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics, Inc.                  | Cytokinetics, Inc.                  | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |       679 | NS      | $42906.01     | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Daiichi Sankyo Co. Ltd.             | Daiichi Sankyo Co. Ltd.             | CUSIP: N/A<br>LEI: 353800XGIU2IHQGC9504       | Long             | EC               | CORP              | JP        |      3200 | NS      | $58622.82     | 0.67%             |  |  |  | No            |                  2 | On Loan: No      |
| Xenon Pharmaceuticals, Inc.         | Xenon Pharmaceuticals, Inc.         | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |       913 | NS      | $37442.13     | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S                    | Novo Nordisk A/S, Class B           | CUSIP: N/A<br>LEI: 549300DAQ1CVT6CXN342       | Long             | EC               | CORP              | DK        |      5388 | NS      | $319935.37    | 3.65%             |  |  |  | No            |                  2 | On Loan: No      |
| Danish Krone                        | Danish Krone                        | CUSIP: N/A<br>LEI: N/A                        | Short            | STIV             |  | DK        |        -0 | OU      | $0.00         | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Swiss Franc                         | Swiss Franc                         | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             |  | CH        |         0 | OU      | $0.06         | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Hoya Corp.                          | Hoya Corp.                          | CUSIP: N/A<br>LEI: 353800X4VR3BHEUCJB42       | Long             | EC               | CORP              | JP        |      1000 | NS      | $167755.89    | 1.91%             |  |  |  | No            |                  2 | On Loan: No      |
| McKesson Corp.                      | McKesson Corp.                      | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |       221 | NS      | $183697.41    | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic plc                       | Medtronic plc                       | CUSIP: N/A<br>LEI: 549300GX3ZBSQWUXY261       | Long             | EC               | CORP              | IE        |      2643 | NS      | $272123.28    | 3.10%             |  |  |  | No            |                  1 | On Loan: No      |
| British Pound                       | British Pound                       | CUSIP: N/A<br>LEI: N/A                        | Short            | STIV             |  | GB        |        -0 | OU      | $-0.18        | -0.00%            |  |  |  | No            |                  1 | On Loan: No      |
| CG oncology, Inc.                   | CG oncology, Inc.                   | CUSIP: 156944100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1052 | NS      | $54756.60     | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                           | Argenx SE                           | CUSIP: N/A<br>LEI: 7245009C5FZE6G9ODQ71       | Long             | EC               | CORP              | NL        |       218 | NS      | $183331.78    | 2.09%             |  |  |  | No            |                  2 | On Loan: No      |
| Alnylam Pharmaceuticals, Inc.       | Alnylam Pharmaceuticals, Inc.       | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |        84 | NS      | $28397.04     | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                 | Ascendis Pharma A/S                 | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |       297 | NS      | $67151.70     | 0.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics, Inc.           | Axsome Therapeutics, Inc.           | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |       429 | NS      | $79043.25     | 0.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Cardinal Health, Inc.               | Cardinal Health, Inc.               | CUSIP: 14149Y108<br>LEI: CCU46N3GJMF4OK4N7U60 | Long             | EC               | CORP              | US        |       679 | NS      | $145903.52    | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Israeli Shekel                      | Israeli Shekel                      | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             |  | IL        |      1840 | OU      | $593.67       | 0.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals, Inc.        | Vertex Pharmaceuticals, Inc.        | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |       344 | NS      | $161645.60    | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                    | Roche Holding AG                    | CUSIP: N/A<br>LEI: 549300U41AUUVOAAOB37       | Long             | EC               | CORP              | CH        |       564 | NS      | $256473.32    | 2.92%             |  |  |  | No            |                  2 | On Loan: No      |
| Cigna Group (The)                   | Cigna Group (The)                   | CUSIP: 125523100<br>LEI: 549300VIWYMSIGT1U456 | Long             | EC               | CORP              | US        |       142 | NS      | $38923.62     | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Legend Biotech Corp.                | Legend Biotech Corp.                | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             | EC               | CORP              | KY        |       167 | NS      | $2922.50      | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp.          | Edwards Lifesciences Corp.          | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |      1781 | NS      | $144902.16    | 1.65%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                          | Genmab A/S                          | CUSIP: N/A<br>LEI: 529900MTJPDPE4MHJ122       | Long             | EC               | CORP              | DK        |       199 | NS      | $64831.31     | 0.74%             |  |  |  | No            |                  2 | On Loan: No      |
| Convatec Group plc                  | Convatec Group plc                  | CUSIP: N/A<br>LEI: 213800LS272L4FIDOH92       | Long             | EC               | CORP              | GB        |     16261 | NS      | $51292.39     | 0.58%             |  |  |  | Yes           |                  2 | On Loan: No      |
| IQVIA Holdings, Inc.                | IQVIA Holdings, Inc.                | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |       544 | NS      | $125201.60    | 1.43%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca plc                     | AstraZeneca plc                     | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |      2242 | NS      | $417716.20    | 4.76%             |  |  |  | No            |                  2 | On Loan: No      |
| Fresenius SE & Co. KGaA             | Fresenius SE & Co. KGaA             | CUSIP: N/A<br>LEI: XDFJ0CYCOO1FXRFTQS51       | Long             | EC               | CORP              | DE        |      1875 | NS      | $104883.41    | 1.19%             |  |  |  | No            |                  2 | On Loan: No      |
| Lonza Group AG                      | Lonza Group AG (Registered)         | CUSIP: N/A<br>LEI: 549300EFW4H2TCZ71055       | Long             | EC               | CORP              | CH        |       252 | NS      | $171221.46    | 1.95%             |  |  |  | No            |                  2 | On Loan: No      |
| HCA Healthcare, Inc.                | HCA Healthcare, Inc.                | CUSIP: 40412C101<br>LEI: 529900PH4ZGUH2MNEU89 | Long             | EC               | CORP              | US        |        60 | NS      | $29296.20     | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical, Inc.            | Intuitive Surgical, Inc.            | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |       235 | NS      | $118491.70    | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie, Inc.                        | AbbVie, Inc.                        | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |      2129 | NS      | $474788.29    | 5.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals, Inc.     | Regeneron Pharmaceuticals, Inc.     | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |       247 | NS      | $183138.15    | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group, Inc.            | UnitedHealth Group, Inc.            | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |      1067 | NS      | $306154.31    | 3.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific, Inc.      | Thermo Fisher Scientific, Inc.      | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |       254 | NS      | $146966.94    | 1.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                         | Novartis AG (Registered)            | CUSIP: N/A<br>LEI: 5493007HIVTX6SY6XD66       | Long             | EC               | CORP              | CH        |       672 | NS      | $99704.52     | 1.14%             |  |  |  | No            |                  2 | On Loan: No      |
| CVS Health Corp.                    | CVS Health Corp.                    | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |      2827 | NS      | $210668.04    | 2.40%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                              | UCB SA                              | CUSIP: N/A<br>LEI: 2138008J191VLSGY5A09       | Long             | EC               | CORP              | BE        |       544 | NS      | $165770.79    | 1.89%             |  |  |  | No            |                  2 | On Loan: No      |
| EURO                                | EURO                                | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             |  | XX        |       717 | OU      | $850.36       | 0.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Align Technology, Inc.              | Align Technology, Inc.              | CUSIP: 016255101<br>LEI: 549300N5YSE0U3LCP840 | Long             | EC               | CORP              | US        |       228 | NS      | $37170.84     | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Terns Pharmaceuticals, Inc.         | Terns Pharmaceuticals, Inc.         | CUSIP: 880881107<br>LEI: 254900S1ZDQMF4MYP709 | Long             | EC               | CORP              | US        |       903 | NS      | $31243.80     | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-03-02

**Name of Applicant:** J.P. Morgan Exchange-Traded Fund Trust

**Signature:** Timothy J. Clemens

**Name of Signer:** Timothy J. Clemens

**Title:** Treasurer and Principal Financial Officer